The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme
Sign Up to like & getrecommendations! Published in 2017 at "European Journal of Pharmacology"
DOI: 10.1016/j.ejphar.2017.05.064
Abstract: ABSTRACT In epithelial tumors, the epidermal growth factor receptor (EGFR) controls key signaling pathways responsible for growth, proliferation, migration, and survival of tumor cells. The epidermal growth factor receptor variant III (EGFRvIII) is the most… read more here.
Keywords: egfr; egfrviii; glioblastoma multiforme; variant iii ... See more keywords
EGFRvIII expression triggers a metabolic dependency and therapeutic vulnerability sensitive to autophagy inhibition
Sign Up to like & getrecommendations! Published in 2018 at "Autophagy"
DOI: 10.1080/15548627.2017.1409926
Abstract: ABSTRACT Expression of EGFRvIII is frequently observed in glioblastoma and is associated with increased cellular proliferation, enhanced tolerance to metabolic stresses, accelerated tumor growth, therapy resistance and poor prognosis. We observed that expression of EGFRvIII… read more here.
Keywords: autophagy inhibition; glioblastoma; egfrviii; expression ... See more keywords
Bispecific T-Cell Engager -Armored Chimeric Antigen Receptor T Cells Overcome Antigen Escape From EGFRvIII-Targeted Therapy For Glioblastoma
Sign Up to like & getrecommendations! Published in 2019 at "Neurosurgery"
DOI: 10.1093/neuros/nyz310_154
Abstract: Immune therapy with T cells engineered to express chimeric antigen receptors (CARs) represents a promising therapy for patients with glioblastoma (GBM). However, clinical responses have been limited due to heterogeneous target antigen expression and outgrowth… read more here.
Keywords: therapy; antigen; car cells; egfr ... See more keywords
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Sign Up to like & getrecommendations! Published in 2017 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.aaa0984
Abstract: A trial of autologous T cells redirected to a specific mutation in glioblastoma patients illustrates mechanisms of resistance. Speeding toward CAR T cell therapy for glioblastoma Chimeric antigen receptor (CAR) T cells have been successfully… read more here.
Keywords: glioblastoma; egfrviii; cart egfrviii; car cells ... See more keywords
Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-17-0890
Abstract: Purpose: Approximately 40% of all glioblastomas have amplified the EGFR gene, and about half of these tumors express the EGFRvIII variant. The prognostic role of EGFRvIII in EGFR-amplified glioblastoma patients and changes in EGFRvIII expression… read more here.
Keywords: egfr amplified; amplified glioblastomas; egfrviii positivity; egfrviii ... See more keywords
Highly Sensitive EGFRvIII Detection in Circulating Extracellular Vesicle RNA of Glioma Patients
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-22-0444
Abstract: Abstract Purpose: Liquid biopsy offers an attractive platform for noninvasive tumor diagnosis, prognostication, and prediction of glioblastoma clinical outcomes. Prior studies report that 30% to 50% of GBM lesions characterized by EGFR amplification also harbor… read more here.
Keywords: egfrviii; rna; detection; glioma ... See more keywords
Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII
Sign Up to like & getrecommendations! Published in 2021 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-20-0508
Abstract: AMG 596 is a bispecific T-cell engager (BiTE) immuno-oncology therapy in clinical development for treatment of glioblastoma multiforme (GBM), the most common primary brain tumor in adults with limited therapeutic options. AMG 596 is composed… read more here.
Keywords: gbm cells; amg 596; tumor; cell ... See more keywords
Abstract LB-066: BiTE-armored CARs overcome antigen escape in EGFRvIII-targeted therapy for glioblastoma
Sign Up to like & getrecommendations! Published in 2019 at "Immunology"
DOI: 10.1158/1538-7445.am2019-lb-066
Abstract: Glioblastoma (GBM) is a devastating disease with an extremely poor prognosis. Immune therapy with T cells engineered to express chimeric antigen receptors (CARs), represents a promising alternative to conventional therapy, but responses have been limited… read more here.
Keywords: therapy; egfrviii targeted; bite; egfr ... See more keywords